Compare Paychex, Inc. (PAYX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Paychex, Inc. trades at $111.32 (market cap $39.82B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Paychex, Inc. is far larger — about 24.4× Recursion Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 4.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PAYX | RXRX | |
|---|---|---|
Market Cap | $39.82B | $1.63B |
Sector | Industrials | Health |
52-Week High | $147.99 | $6.79 |
52-Week Low | $85.57 | $2.84 |
Enterprise Value | $43.31B | $1.05B |
Dividend Yield | 4.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
